Table 3 The frequency CNV in 37 SDCs by NanoString nCounter analysis
From: High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma
Gene | Case no. | Copy number amplification no. (%) | Copy number loss no. (%) | Total CNV frequency no. (%) |
|---|---|---|---|---|
AURKA | 37 | 0 (0) | 4 (10.8) | 4 (10.8) |
CCND1 | 37 | 31 (83.7) | 0 (0) | 31 (83.7) |
CCNE1 | 37 | 2 (5.4) | 5 (13.5) | 7 (18.9) |
CDK4 | 37 | 34 (91.8) | 0 (0) | 34 (91.8) |
CDK6 | 37 | 6 (16.2) | 4 (10.8) | 10 (27) |
CDKN1A | 37 | 37 (100) | 0 (0) | 37 (100) |
CDKN2A | 37 | 10 (27) | 3 (8.1) | 13 (35.1) |
EGFR | 37 | 30 (81) | 0 (0) | 30 (81) |
ERBB2 | 37 | 37 (100) | 0 (0)) | 37 (100) |
ERBB3 | 37 | 30 (81) | 0 (0) | 30 (81) |
FGFR1 | 37 | 8 (21.6) | 1 (2.7) | 9 (24.3) |
FGFR2 | 37 | 3 (8.1) | 2 (5.4) | 5 (13.5) |
IGF1R | 37 | 0 (0) | 14 (37.8) | 14 (37.8) |
KLF5 | 37 | 32 (86.4) | 0 (0) | 32 (86.4) |
KRAS | 37 | 37 (100) | 0 (0) | 37 (100) |
MDM2 | 37 | 5 (13.5) | 2 (5.4) | 7 (18.9) |
MET | 37 | 24 (64.8) | 0 (0) | 24 (64.8) |
MITF | 37 | 0 (0) | 16 (43.2) | 16 (43.2) |
MYC | 37 | 27 (72.9) | 0 (0) | 27 (72.9) |
PIK3CA | 37 | 3 (8.1) | 14 (37.8) | 17 (45.9) |
TNIK | 37 | 5 (13.5) | 4 (10.8) | 9 (24.3) |